Luminescent nanoparticles synthesized via bio-based protocols that generate nanoparticles
having different chemical compositions along with other functionalities (size and …

Leishmaniasis is a serious and endemic infectious disease that has been reported in more
than 90 countries and territories. The classical treatment presents a series of problems …

Since Leishmania parasites exhibit resistance outbreaks to drugs conventionally used in
medical treatments, research of new antileishmanial compounds or alternative treatment …

Cutaneous leishmaniasis (CL) is a neglected disease prevalent in tropical countries with the
ability to cause skin lesions. Photodynamic therapy (PDT) represents a specific and topical …

Antiparasitic photodynamic therapy (ApPDT) is an emerging approach to manage
cutaneous leishmaniasis (CL) since no side effects, contraindications and parasite …

The cutaneous leishmaniasis is caused by the protozoan of the genus Leishmania. It is
considered by WHO as a public health issue and a neglected disease, which affects rural …

Background Pentavalent antimonials remain first-line drugs in the treatment of cutaneous
leishmaniasis (CL); however, adverse effects and drug resistance have led to the search for …

Leishmaniasis is a neglected disease that impacts more than one billion people in endemic
areas of the globe. Several drawbacks are associated with the currently existing drugs for …

Leishmaniasis is a serious and neglected disease that affects 14 million people around the
World. The currently available drugs for treatment present several drawbacks such as low …

Background In vitro and in vivo testing of new technology was performed to evaluate the
antiplasmodial activity of Photonic Multiphase Modulators (PMM) in cultures and in mice …